Treatment Protocols

In 2013–2014, new therapies, named DAAs, were developed and approved by the international authorities, FDA and European Medicine Agency, that act directly on hepatitis C virus at various points in the viral life cycle and therefore were able to reach above 90% success rates without the need for interferon in most cases and with minimal and tolerable side effects. They are currently approved and available in Egypt as part of the national campaign against hepatitis.

The Egyptian NCCVH has adopted different protocols according to the different patient profiles and in alignment with the most recent international management guidelines 2016 [e.g., the American Association for the study of Disease (AASLD) and the European Association for the Study of the Liver (EASL)].

Treatment of hepatitis C virus has traditionally been difficult because of low rates of treatment success and high rates of treatment discontinuation due to side effects. In recent years, standard therapy consisted of pegylated interferon α and ribavirin, treatment extended for a long period of up to one year and included weekly injections yet results were unsatisfactory in the range of 40%, and patients suffered from severe side effects, including anemia and blood related disorders.

References:

  • Jazwinski AB, Muir AJ. Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol Hepatol (N Y). 2011; 7 (3): 154-62.
  • National Committee for Control of Viral Hepatitis (NCCVH). 02/2016
Protocol No. of Patients
Interferon/Sofosbuvir/Ribavirin1 64,188
Sofosbuvir /Ribavirin 24,178
Sofosbuvir/Simeprevir 30,319
Sofosbuvir/Daclatasvir 92,239
Sofosbuvir/Daclatasvir/Ribavirin 61,570